### Edgar Filing: MANHATTAN PHARMACEUTICALS INC - Form 4

MANHAT Form 4 March 28, 2	TAN PHARMAC	EUTICAI	LS INC								
FORM	ЛЛ								PPROVAL		
	UNITED	Washington, D.C. 20549							3235-0287		
Check t if no los subject Section Form 4 Form 5	nger to <b>STATEN</b> 16. or			CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES					Expires: January 31 2009 Estimated average burden hours per response 0.5		
obligati may co <i>See</i> Inst 1(b).	ons ntinue. Section 17(	(20)(h) of the Investment Commenty A of $(10)(1)$									
(Print or Type	Responses)										
1. Name and Address of Reporting Person <u>*</u> WEISER MICHAEL			2. Issuer Name <b>and</b> Ticker or Trading Symbol				5. Relationship Issuer	5. Relationship of Reporting Person(s) to Issuer			
		MANHATTAN PHARMACEUTICALS INC				(Cł	(Check all applicable)				
			[MHAN]				XDirector	XDirector10% Owner Officer (give titleOther (specify			
	, , , , , , , , , , , , , , , , , , ,	Middle) C., 810		of Earliest T Day/Year) 2008	ransaction		below)	below)	ler (specify		
				endment, D onth/Day/Yea	-	1	Applicable Line) _X_ Form filed b	<ul> <li>6. Individual or Joint/Group Filing(Check</li> <li>Applicable Line)</li> <li>_X_ Form filed by One Reporting Person</li> <li> Form filed by More than One Reporting</li> </ul>			
							Person				
(City)	(State)	(Zip)	Tab	ole I - Non-l	Derivative	Securiti	es Acquired, Disposed	l of, or Beneficia	Illy Owned		
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemo Execution any (Month/Da	Date, if	3. Transactio Code (Instr. 8)	4. Securit nAcquired Disposed (Instr. 3, 4	(A) or of (D) 4 and 5) (A) or	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) . (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
				Code V	Amount	(D) Pr	rice				
Reminder: Re	port on a separate line	e for each cla	ass of sec	urities bene	Perso inform requir	ns who nation c red to re	tly or indirectly. respond to the coll contained in this for espond unless the for rrently valid OMB c	m are not orm	SEC 1474 (9-02)		

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

number.

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transacti Code (Instr. 8)	5. Number orDerivative Securities Acquired ( or Disposed (D) (Instr. 3, 4, and 5)	A) d of	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)	
				Code V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Warrant	\$ 1.21						01/27/2004	01/27/2009	Common Stock	103,655
Stock Options	\$ 1.65						<u>(1)</u>	01/27/2014	Common Stock	75,000
Warrant	\$ 1.44						(2)	08/30/2010	Common Stock	24,099
Stock Options	\$ 1						(3)	01/11/2015	Common Stock	30,000
Stock Options	\$ 0.71						<u>(4)</u>	01/30/2017	Common Stock	50,000
Stock Options	\$ 0.17	03/25/2008		А	75,000		(5)	03/25/2018	Common Stock	75,000

### Edgar Filing: MANHATTAN PHARMACEUTICALS INC - Form 4

# **Reporting Owners**

Reporting Owner Name / AddressRelationsityImage: Constraint of the second second

Weiser	03/25/2008				
<u>**</u> Signature of Reporting Person	Date				

## **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) 75,000 shares have vested.
- (2) Immediately
- (3) 10,000 shares vest on each of 1/11/05, 1/11/06, and 1/11/07.
- (4) 16,667 shares vest on each of 1/30/07 and 1/30/08; 16,666 shares vest on 1/30/09.

#### Edgar Filing: MANHATTAN PHARMACEUTICALS INC - Form 4

(5) 41,667 shares vest on the grant date, 3/25/08, an additional 16,667 shares vest on 3/25/09 and an additional 16,666 shares vest on 3/25/10.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.